🔴 BioCryst Pharmaceuticals is trading 6.5% down today after Pharvaris’s positive late-stage hereditary-angioedema results

BioCryst Pharmaceuticals is trading 6.5% down at $8.23 after continued pressure from Pharvaris’s positive late-stage hereditary-angioedema trial results, which demonstrated an 83% reduction in monthly attacks versus placebo.

• The decline comes during a weaker September 10 market, with the S&P 500 down 0.56% and Nasdaq Composite down 0.79%.
• Available evidence points to sector-specific competitive concerns compounded by broader risk-off sentiment, rather than a new BioCryst announcement.